

CHAPTER ONE: INTRODUCTION.....	1
REASONS FOR DOING THE STUDY	1
STUDY GOALS AND OBJECTIVES.....	1
METHODOLOGIES AND INFORMATION SOURCES.....	2
ANALYST CREDENTIALS.....	2
RELATED BCC REPORTS	2
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
CHAPTER TWO: SUMMARY.....	4
SUMMARY (CONTINUED)	4
<i>SUMMARY TABLE GLOBAL MARKET FOR HAI TREATMENTS,</i> <i>THROUGH 2016 (\$ MILLIONS)</i>	5
<i>SUMMARY FIGURE GLOBAL MARKET FOR HAI TREATMENTS BY</i> <i>GEOGRAPHICAL AREA, 2010 AND 2016 (%)</i>	6
CHAPTER THREE: OVERVIEW	7
<i>TABLE 1 GLOBAL PREVALENCE OF HEALTHCARE-ACQUIRED</i> <i>INFECTIONS (PER 100 PATIENTS)</i>	7
<i>TABLE 1 (CONTINUED)</i>	8
IMPORTANCE OF HAND WASHING	8
MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS.....	9
<i>TABLE 2 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED</i> <i>INFECTIONS</i>	9
<i>TABLE 2 (CONTINUED)</i>	10
GRAM-POSITIVE BACTERIA.....	10
<i>S. AUREUS</i>	11
Transmission Routes	11
MRSA	11
Rate of Infection.....	11
Transmission Routes	12
TYPES OF PNEUMONIA.....	13
Pseudomonas Aeruginosa.....	13
Hospital-Acquired Pneumonia	13
Klebsiella Pneumonia.....	13
<i>CLOSTRIDIUM DIFFICILE</i>	14
<i>MYCOBACTERIUM TUBERCULOSIS</i>	14
Scope of Infection	14
<i>E. COLI</i>	15
UTI Treatment Options.....	15
GASTROENTERITIS-CAUSING BACTERIA.....	15
Treatment Options	16
VANCOMYCIN-RESISTANT ENTEROCOCCI	16
Types of VRE	16

LEGIONELLA BACTERIA.....	16
Treatment Options	17
GRAM-NEGATIVE BACTERIA.....	17
PSEUDOMONAS AERUGINOSA.....	17
ACINETOBACTER BAUMANNII	18
STENOTROPHOMONAS MALTOPHILIA	18
VIRAL INFECTIONS	19
VIRAL INFECTION RESEARCH	19
HEPATITIS B AND C	19
Scope of Infection	20
Treatment	20
HIV.....	20
Treatment	21
NOROVIRUS.....	21
INFLUENZA VIRUS.....	21
Influenzavirus A, B, C	21
Transmission	22
Symptoms.....	22
Treatment	22
RESPIRATORY SYNCYTIAL VIRUS.....	23
Treatment	23
FUNGAL INFECTIONS.....	23
ASPERGILLUS INFECTIONS	23
Treatment	24
YEAST INFECTIONS.....	24
Candida Infections.....	24
PREVENTING HAI	25
DETERMINING THE MODE OF TRANSMISSION	25
CDC RECOMMENDATIONS FOR PREVENTION	26
<i>TABLE 3 CDC MEASURES FOR PREVENTION OF HEALTHCARE-</i>	
<i>ACQUIRED INFECTIONS, 2007</i>	<i>26</i>
<i>TABLE 3 (CONTINUED).....</i>	<i>27</i>
ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION	
CONTROL INDIVIDUALS	27
<i>TABLE 4 SELECTED RESPONSIBILITIES OF INFECTION CONTROL</i>	
<i>TEAM MEMBERS</i>	<i>28</i>
<i>TABLE 4 (CONTINUED).....</i>	<i>29</i>
COMPONENTS OF A HAI SURVEILLANCE SYSTEM.....	30
<i>TABLE 5 MAIN STEPS AND COMPONENTS IN DEVELOPING AN</i>	
<i>EFFECTIVE INFECTION-CONTROL SURVEILLANCE SYSTEM</i>	<i>30</i>
SUITABLE SURVEYS IN DEVELOPING COUNTRIES.....	30
HEALTHCARE INFECTION POINTS OF GENERATION	31
HOSPITALS	31
SURGICAL PROCEDURES	31

AMBULATORY SURGERY CENTERS IN THE U.S.....	31
Number of Procedures in ASCs.....	32
Infection Control in ASCs	32
DIALYSIS CENTERS	32
U.S. Dialysis Centers	32
Transmission of VRE.....	33
Hepatitis Transmission in U.S. Dialysis Centers	33
Hepatitis Transmission in Dialysis Centers Outside the U.S.	33
ASSISTED LIVING AND LONG-TERM CARE FACILITIES.....	34
TREATMENTS	34
PROACTIVE MEASURES.....	34
Environmental Controls.....	35
Device Design.....	35
REACTIVE MEASURES	35
CHANGES IN THE INDUSTRY.....	35
<i>TABLE 6 SELECTED MERGERS AND/OR ACQUISITIONS, 2005–2011</i> <i>(\$ MILLIONS)</i>	36

CHAPTER FOUR: GLOBAL HEALTHCARE-ACQUIRED INFECTION

MARKET	37
U.S. MARKET.....	37
U.S. HEALTHCARE SPENDING	37
SCOPE OF HEALTHCARE-ACQUIRED INFECTIONS IN U.S.	38
Ventilator-Associated Pneumonia	38
RATE OF INFECTION	39
Intensive Care Units	39
Surgical Site Infections	39
Fungal Infections.....	40
COSTS	40
U.S. PREVENTION ACTION PLAN	41
<i>TABLE 7 HHS ACTION PLAN FOR HAI PREVENTION (%</i> <i>REDUCTION)</i>	41
EUROPEAN MARKET	42
SCOPE	42
HELICS.....	42
RATE OF INFECTION AND COSTS	42
JAPANESE MARKET	43
SCOPE	43
RATE OF INFECTION	44
CHINESE MARKET	45
SCOPE	45
RATE OF INFECTION	45
REST OF THE WORLD MARKET	45
SCOPE	46

RATE OF INFECTION	46
Rate of Infection (Continued).....	47
OPPORTUNITIES AND CHALLENGES FOR HAI INDUSTRY	48
MEDICAL DEVICE OPPORTUNITIES AND CHALLENGES	48
Challenges.....	48
ENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES AND CHALLENGES	49
Challenges.....	49
NEW TREATMENTS.....	49
PHARMACEUTICAL MARKET OPPORTUNITIES AND CHALLENGES	49
Patent Expiry.....	50
<i>TABLE 8 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS, 2005–2020.....</i>	<i>50</i>
Pipeline Limitations	50
Global Recession	51
Regulatory Restrictions.....	51
Generic Competition.....	51
IMPACT OF DEMOGRAPHIC CHANGES	52
DEMOGRAPHIC CHANGES IN THE U.S.....	52
DEMOGRAPHIC CHANGES OUTSIDE THE U.S.....	52
Demographic Changes Outside the U.S. (Continued).....	53
CHAPTER FIVE: HAI PHARMACEUTICAL MARKET	54
GLOBAL MARKETS	54
ROLE OF EMERGING NATIONS.....	54
PHARMACEUTICALS USED FOR HEALTHCARE-ACQUIRED INFECTIONS	55
<i>TABLE 9 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH 2016 (\$ MILLIONS).....</i>	<i>55</i>
GLOBAL GROWTH RATES FOR PHARMACEUTICALS.....	55
<i>TABLE 10 ESTIMATED GROWTH OF PHARMACEUTICAL HEALTHCARE SPENDING BY REGION, THROUGH 2016 (%).....</i>	<i>56</i>
VIRAL HAI PHARMACEUTICALS.....	56
<i>TABLE 11 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION, AND MANUFACTURER, 2010.....</i>	<i>57</i>
<i>FIGURE 1 ESTIMATED GLOBAL MARKET SHARE FOR PRESCRIPTION PHARMACEUTICALS TO TREAT VIRAL HAI BY COMPANY, 2010 (%).....</i>	<i>58</i>
<i>FIGURE 2 GLOBAL MARKET FOR VIRAL BY DISEASE TYPE(%)</i>	<i>59</i>
VIRAL PHARMACEUTICAL MARKET BY CONDITION	59
<i>TABLE 12 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI BY CONDITION, THROUGH 2016 (\$ MILLIONS).....</i>	<i>60</i>
BACTERIAL HAI PHARMACEUTICALS.....	60

<i>TABLE 13 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION, AND MANUFACTURER, 2010</i>	60
<i>TABLE 13 (CONTINUED)</i>	61
DRUG CLASSES.....	61
Aminoglycosides	62
B-Lactam Antibiotics.....	62
Cephalosporins.....	62
Glycopeptides.....	63
Lincosamides	63
Lipopeptides.....	63
Carbapenems	63
Penicillins.....	64
Polypeptides.....	64
Macrolides	65
Quinolones	65
Tetracyclines.....	65
Tuberculosis	65
Sulfonamides	65
Other Formulations.....	65
<i>FIGURE 3 GLOBAL MARKET SHARE FOR PRESCRIPTION PHARMACEUTICALS TO TREAT BACTERIAL HAI BY COMPANY, 2010 (%)</i>	66
<i>TABLE 14 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL HAI, THROUGH 2016 (\$ MILLIONS)</i>	67
<i>TABLE 15 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL HAI BY CONDITION, THROUGH 2016 (\$ MILLIONS)</i>	68
FUNGAL HAI PHARMACEUTICALS	68
<i>TABLE 16 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS BY NAME, TYPE, AND MANUFACTURER, 2010</i>	68
<i>TABLE 17 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI, THROUGH 2016 (\$ MILLIONS)</i>	69
<i>FIGURE 4 MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI BY COMPANY, 2010 (%)</i>	70
GLOBAL OPPORTUNITIES.....	70
CHAPTER SIX: HAI ENVIRONMENTAL TREATMENT MARKET.....	72
GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET	72
<i>TABLE 18 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 (\$ MILLIONS)</i>	72
PLANNING FOR CONSTRUCTION OR RENOVATION: U.S.	73
Plans Involving Infection Control.....	73
AIR TREATMENT	73
ROOM FILTRATION SYSTEMS	74

ROOM PRESSURIZATION	75
HYDROGEN PEROXIDE VAPOR	75
Dedicated Airborne Isolation Rooms	76
WATER TREATMENT	76
DESIGN OF SINKS AND OTHER WATER FACILITIES	76
CLEANING PHYSICAL SURFACES	76
DISINFECTION	77
Advantages and Disadvantages of Disinfectants	77
<i>TABLE 19 ADVANTAGES AND DISADVANTAGES OF COMMONLY USED DISINFECTANTS</i>	78
<i>TABLE 19 (CONTINUED)</i>	79
PHENOLICS	79
OXIDIZING AGENTS	79
HALOGENS	80
ALDEHYDES	80
QUATERNARY AMINES	80
ALCOHOLS	81
<i>TABLE 20 GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 (\$ MILLIONS)</i>	81
<i>FIGURE 5 GLOBAL MARKET FOR DISINFECTANT PRODUCTS BY TYPE, 2010 (%)</i>	81
<i>FIGURE 5 (CONTINUED)</i>	82
PATIENT SKIN PREPARATION DISINFECTANTS	82
IODINE.....	82
POVIDONE-IODINE SOLUTIONS	83
CHLORHEXIDINE GLUCONATE	83
<i>TABLE 21 GLOBAL MARKET FOR PATIENT PREPARATION DISINFECTANTS, THROUGH 2016 (\$ MILLIONS)</i>	83
STERILIZATION SYSTEMS FOR INFECTION CONTROL.....	84
<i>TABLE 22 GLOBAL MARKET FOR STERILIZATION DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 (\$ MILLIONS)</i>	84
CHEMICAL STERILIZATION.....	85
ETO Sterilization.....	85
Major Players in Chemical Sterilization	86
OTHER CHEMICAL STERILIZATION.....	86
Peracetic Acid	86
Hydrogen Peroxide	86
Chlorine Dioxide	87
Ozone.....	87
STEAM STERILIZATION	87
<i>TABLE 23 SELECTED PLASTIC MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION</i>	88

Autoclaving	88
Major Players in Heat Sterilization.....	89
CHAPTER SEVEN: HAI MEDICAL DEVICES: CATHETERS, PATIENT VENTILATION SYSTEMS, AND IN-LINE STERILIZATION FILTERS	90
TABLE 24 PROJECTED GLOBAL MARKET FOR CATHETERS, PATIENT VENTILATION DEVICES, AND STERILE IV FILTERS, THROUGH 2016 (\$ MILLIONS).....	90
CATHETER MARKET	91
TABLE 25 PROJECTED GLOBAL MARKET FOR URINARY, CVC AND PERIPHERAL CATHETERS THROUGH 2016 (\$ MILLIONS).....	91
SELECTED GLOBAL MEDICAL HAI DEVICE MARKET	91
TABLE 26 GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 (\$ MILLIONS).....	92
CATHETERS	92
USE OF COATINGS.....	93
CATHETER COATINGS	93
TABLE 27 SELECTED CATHETER PRODUCTS WITH ANTIBIOTIC PROPERTIES	93
Silver Coating	94
SURFACE-MODIFIED CATHETER	94
TABLE 28 GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL PROPERTIES, THROUGH 2016 (\$ MILLIONS).....	95
FIGURE 6 HAI ANTIMICROBIAL CATHETER MARKET SHARES BY URINARY, CVC, AND PERIPHERAL SEGMENTS, 2011 AND 2016 (%).....	95
FIGURE 6 (CONTINUED)	96
URINARY TRACT CATHETERS.....	96
CENTRAL VENOUS CATHETERS.....	96
Dialysis Catheters	97
Catheter-Related Bloodstream Infections	97
Catheter-Related Bloodstream Infections (Continued)	98
TABLE 29 POTENTIAL SOURCES OF CRBSI	99
PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS	99
MARKET OPPORTUNITIES FOR CATHETER MANUFACTURERS.....	99
CATHETER GROWTH IN REGIONAL MARKETS	100
TABLE 30 GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2016 (\$ MILLIONS).....	100
FIGURE 7 GLOBAL HAI CATHETER MARKET BY REGION, 2011 AND 2016 (%).....	101
PATIENT VENTILATION DEVICES.....	102

<i>TABLE 31 GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS, THROUGH 2016 (\$ MILLIONS)</i>	102
TYPES OF VENTILATION DEVICES	103
Non-Invasive Ventilators	103
<i>TABLE 32 GLOBAL MARKET FOR NON-INVASIVE VENTILATIONS SYSTEMS FOR USE WITH PATIENTS WHO HAVE HAIS, THROUGH 2016 (\$ MILLIONS)</i>	104
ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS	104
Coated Endotracheal Tubes	104
Tapered Endotracheal Tubes	105
<i>TABLE 33 GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED TO MINIMIZE VAP, THROUGH 2016 (\$ MILLIONS)</i>	105
IN-LINE STERILE IV FILTRATION	105
<i>TABLE 34 GLOBAL STERILE IV FILTER MARKET, THROUGH 2016 (\$ MILLIONS)</i>	106
CHAPTER EIGHT: REGULATIONS AND PATENTS.....	107
U.S. INFECTION CONTROL PROGRAMS	107
INFECTION CONTROL MEASURES AND PROTOCOLS	108
U.S. REGULATIONS.....	108
HOSPITAL INFECTIONS DISCLOSURE ACT	108
CURRENT AND PENDING REQUIREMENTS	108
Affordable Care Act and Implications for the Pharmaceutical Industry	109
Biosimilars	109
CMS Reimbursement for HAIs	110
EUROPEAN REGULATIONS	110
IMPLICATIONS FOR PHARMACEUTICAL MANUFACTURERS.....	110
JAPANESE REGULATIONS	111
CHINESE REGULATIONS	112
PATENTS.....	112
PATENTS BY MANUFACTURER.....	112
<i>TABLE 35 PATENTS BY MANUFACTURER, 2005–2011</i>	113
<i>TABLE 35 (CONTINUED)</i>	114
<i>TABLE 35 (CONTINUED)</i>	115
PATENTS BY DATE OF ISSUE	115
<i>TABLE 36 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, 2005– 2011</i>	116
<i>TABLE 36 (CONTINUED)</i>	117
PATENTS BY MANUFACTURER.....	117
<i>TABLE 37 PATENTS BY MANUFACTURER</i>	117
<i>TABLE 37 (CONTINUED)</i>	118
PATENTS FOR DELIVERY OF PHARMACEUTICALS.....	119

<i>TABLE 38 PATENT BY INDICATION: PHARMACEUTICAL DELIVERY, 2005–2011</i>	119
BACTERIAL PHARMACEUTICAL PATENTS.....	119
<i>TABLE 39 PATENTS BY INDICATION: BACTERIAL PHARMACEUTICAL, 2005–2011</i>	120
<i>TABLE 39 (CONTINUED)</i>	121
<i>TABLE 39 (CONTINUED)</i>	122
<i>TABLE 39 (CONTINUED)</i>	123
FUNGAL PHARMACEUTICAL PATENTS	123
<i>TABLE 40 PATENT BY INDICATION: FUNGAL PHARMACEUTICAL, 2010</i>	123
VIRAL PHARMACEUTICAL PATENTS.....	124
<i>TABLE 41 PATENTS BY INDICATION: VIRAL PHARMACEUTICAL, 2005–2011</i>	124
<i>TABLE 41 (CONTINUED)</i>	125
<i>TABLE 41 (CONTINUED)</i>	126
ENVIRONMENTAL CONTROLS	127
<i>TABLE 42 PATENT BY INDICATION: AIR FILTRATION, 2005–2011</i>	127
<i>TABLE 43 PATENTS BY INDICATION: WATER TREATMENT, 2005–2011</i>	128
PATENTS FOR SURFACE DISINFECTANTS.....	128
<i>TABLE 44 PATENTS BY INDICATION: DISINFECTANT SURFACES, 2005–2011</i>	129
<i>TABLE 44 (CONTINUED)</i>	130
<i>TABLE 44 (CONTINUED)</i>	131
<i>TABLE 45 PATENT BY INDICATION: SOLID WASTE TREATMENT, 2005–2011</i>	132
PATENTS FOR DIAGNOSTIC PROCESSES	132
<i>TABLE 46 PATENTS BY INDICATION: DIAGNOSTIC, 2006–2011</i>	133
<i>TABLE 46 (CONTINUED)</i>	134
MEDICAL DEVICES	134
<i>TABLE 47 PATENTS BY INDICATION: CATHETER, 2008–2011</i>	134
<i>TABLE 47 (CONTINUED)</i>	135
<i>TABLE 47 (CONTINUED)</i>	136
<i>TABLE 47 (CONTINUED)</i>	137
<i>TABLE 48 PATENTS BY INDICATION: ANTIMICROBIAL COATINGS, 2005–2011</i>	137
<i>TABLE 48 (CONTINUED)</i>	138
<i>TABLE 48 (CONTINUED)</i>	139
<i>TABLE 48 (CONTINUED)</i>	140
<i>TABLE 48 (CONTINUED)</i>	141
<i>TABLE 48 (CONTINUED)</i>	142
CHAPTER NINE: CURRENT RESEARCH AND EMERGING THERAPIES	143
EMERGING RESEARCH.....	143

RAPID TESTING	143
ANTISEPTIC WASHES	144
PHARMACEUTICALS	144
MERCK.....	144
Boceprivir	144
VERTEX	144
Teleprivir	144
TIBOTEC.....	145
CEREXA	145
Ceftaroline	145
NXL104.....	145
BASILEA PHARMACEUTICALS	145
Ceftobiprole.....	145
Delafloxacin	146
JOHNSON & JOHNSON.....	146
Doribax.....	146
CUBIST PHARMACEUTICALS	147
CSA-201	147
CXA183,315	147
TOYAMA CHEMICAL.....	147
T-705	147
T-3912	147
T-2307	148
GLAXOSMITHKLINE	148
OPTIMER PHARMACEUTICALS	148
Fidaxomicin.....	148
AURICX.....	148
BPH-652.....	148
PFIZER	149
THE MEDICINES COMPANY.....	149
Oritavancin	149
STERILIZATION AND DISINFECTION.....	149
SHARKLET TECHNOLOGIES.....	149
HEALTHCARE FACILITY DESIGN.....	150
MEDICAL DEVICE DESIGN	150
ONDINE BIOMEDICAL.....	150
CERAGENIX PHARMACEUTICALS, INC.	150
RENAL SEPSIS MICROFILTER.....	151
CHAPTER TEN: COMPANY PROFILES	152
PHARMACEUTICALS	152
ABBOTT LABORATORIES.....	152
Business Overview	152
Financials.....	152
Products	152

ASTELLAS PHARMA, INC.....	153
Business Overview	153
Financial Information	153
Products	153
ASTRA TECH.....	154
ASTRAZENECA, PLC.....	154
Business Overview	154
Financials.....	154
Products	154
BACTIGUARD, AB	155
Business Overview	155
Financials.....	155
Products	155
BASILEA PHARMACEUTICA, LTD.	155
Business Overview	156
Financials.....	156
Products	156
BAYER, AG (MILES-BAYER)	156
Business Overview	157
Financials.....	157
Products	157
BOEHRINGER INGELHEIM, GMBH.....	157
Business Overview	157
Financials.....	158
Products	158
BRISTOL-MYERS SQUIBB	158
Business Overview	158
Financials.....	158
Products	159
CEREXA, INC. (FOREST LABORATORIES).....	159
Business Overview	159
Financials.....	159
Products	159
CUBIST PHARMACEUTICALS	160
Business Overview	160
Financials.....	160
Products	160
ELAN CORPORATION	161
Business Overview	161
Financials.....	161
Products	162
FOREST LABORATORIES	162
Business Overview	162
Financials.....	162

Products	162
ELI LILLY AND COMPANY.....	163
Business Overview	163
Financials.....	163
Products	163
GILEAD SCIENCES.....	164
Business Overview	164
Financials.....	164
Products	164
GLAXOSMITHKLINE	164
Business Overview	164
Financials.....	165
Products	165
JOHNSON & JOHNSON.....	165
Business Overview	165
Financial Information	166
Products	166
MEDIMMUNE PHARMACEUTICALS	166
Business Overview	166
Financials.....	166
Products	167
MERCK.....	167
Business Overview	167
Financials.....	167
Products	167
NABI BIOPHARMACEUTICALS	168
Business Overview	168
Financials.....	168
Products	169
PFIZER.....	169
Business Overview	169
Financials.....	169
Products	170
ROCHE PHARMACEUTICALS	170
Business Overview	170
Financials.....	170
Products	171
SANOFI AVENTIS.....	171
Business Overview	171
Financials.....	171
Products	172
SCHERING-PLOUGH	172
THE MEDICINES COMPANY.....	172
Business Overview	172

Financials.....	172
Products	172
THERAVANCE	173
Business Overview	173
Financials.....	173
Products	173
TOYAMA CHEMICAL CO, LTD.	174
Business Overview	174
Financials.....	174
Products	174
VERTEX PHARMACEUTICALS, INC.	175
Business Overview	175
Financials.....	175
Products	175
VIROPHARMA, INC.	175
Business Overview	176
Financials.....	176
Products	176
ENVIRONMENTAL PRODUCTS.....	176
3M HEALTHCARE, MEDICAL DIVISION.....	176
Business Overview	176
Financials.....	177
Products	177
ADVANCED STERILIZATION PRODUCTS	177
Business Overview	177
Financials.....	177
Products	178
ANDERSEN PRODUCTS, INC.	178
Business Overview	178
Financials.....	178
Products	179
BAXTER INTERNATIONAL.....	179
Business Overview	179
Financials.....	179
Products	179
DIVERSEY, INC	180
Business Overview	180
Financials.....	180
Products	181
ECOLAB	181
Business Overview	181
Financials.....	181
Products	181
GETINGE USA, INC.....	182

Business Overview	182
Financials.....	182
Products	182
PRIMUS STERILIZER CO., INC.	183
Business Overview	183
Financials.....	183
Products	183
RUHOF CORP.....	183
Business Overview	183
Financials.....	183
Products	184
STERIGENICS.....	184
Business Overview	184
Financials.....	184
Products	184
STERIS CORP.....	185
Business Overview	185
Financials.....	185
Products	185
TUTTANAUER USA CO., LTD.....	186
Business Overview	186
Financials.....	186
Products	186
ULTRAVIOLET DEVICES, INC.....	186
Business Overview	186
Financials.....	187
Products	187
XENEX HEALTHCARE SERVICES.....	187
Business Overview	187
Financials.....	187
Products	187
INFECTION CONTROL DEVICES.....	188
B. BRAUN MELSUNGEN, AG.....	188
Business Overview	188
Financials.....	188
Products	188
BECTON DICKINSON	189
Business Overview	189
Financials.....	189
Products	189
BIOMÉRIEUX, INC.....	190
Business Overview	190
Financials.....	190
Products	191

CANTEL MEDICAL CORP.	191
Business Overview	191
Financials.....	191
Products	191
CAREFUSION CORP.	192
Business Overview	192
Financials.....	192
Products	193
CEPHEID	193
Business Overview	193
Financials.....	193
Products	193
CLOROX CO.....	194
Business Overview	194
Financials.....	194
Products	194
COLOPLAST GROUP	194
Business Overview	195
Financials.....	195
Products	195
CONVATEC.....	195
Business Overview	195
Financial	195
Products	196
COOK MEDICAL.....	196
Business Overview	196
Financials.....	196
Products	197
COVIDIEN, PLC	197
Business Overview	197
Financials.....	197
Products	197
CR BARD	198
Business Overview	198
Financials.....	198
Products	199
DRAGER MEDICAL, LTD., U.K.	199
Business Overview	199
Financials.....	199
Products	200
HOLLISTER, INC.....	200
Business Overview	200
Financials.....	200
Products	200

KIMBERLY-CLARK HEALTHCARE	200
Business Overview	200
Financials.....	201
Products	201
ODINE BIOMEDICAL, INC.....	201
Business Overview	201
Financials.....	202
Products	202
TELEFLEX MEDICAL	202
Business Overview	202
Financials.....	202
Products	203
WELCH ALLYN, INC.....	203
Business Overview	203
Financials.....	203
Products	203